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 1.  Introduction 
 Heart diseases are among the major 
causes of death worldwide. The main diffi -
culties in the treatment of cardiac injuries 
arise from the limited capability of cardiac 
tissue to regenerate itself, i.e., the irrevers-
ibility of cardiac damages, the inability of 
cardiac tissues to tolerate ischemia, and 
the extremely limited period of viability 
of cardiac tissues postischemic injury. [ 1,2 ] 
Until now, the golden standard for treat-
ment of cardiac damage has been heart 
transplantation. However, there is a huge 
gap between the large number of people 
who are approved for heart transplants 
and the small number of available donors, 
creating a severe shortage and thus an 
extreme limitation on the effi ciency of 
this method alone. For example, for every 
77 people who receive a heart transplant, 
20 people die due to shortage while 98 000 
remain on waiting lists of at least 3 years 
 Cardiac tissue damage due to myocardial infarction (MI) is one of the leading 
causes of mortality worldwide. The available treatments of MI include pharma-
ceutical therapy, medical device implants, and organ transplants, all of which 
have severe limitations including high invasiveness, scarcity of donor organs, 
thrombosis or stenosis of devices, immune rejection, and prolonged hospitaliza-
tion time. Injectable hydrogels have emerged as a promising solution for in situ 
cardiac tissue repair in infarcted hearts after MI. In this review, an overview of 
various natural and synthetic hydrogels for potential application as injectable 
hydrogels in cardiac tissue repair and regeneration is presented. The review 
starts with brief discussions about the pathology of MI, its current clinical treat-
ments and their limitations, and the emergence of injectable hydrogels as a 
potential solution for post MI cardiac regeneration. It then summarizes various 
hydrogels, their compositions, structures and properties for potential application 
in post MI cardiac repair, and recent advancements in the application of inject-
able hydrogels in treatment of MI. Finally, the current challenges associated with 
the clinical application of injectable hydrogels to MI and their potential solutions 
are discussed to help guide the future research on injectable hydrogels for trans-
lational therapeutic applications in regeneration of cardiac tissue after MI. 
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in the US alone. [ 3 ] These statistics are even more grim in under-
developed countries where the basic infrastructure required to 
achieve the timely linking of compatible donors to patients on 
waiting lists, and to perform the successful transplant itself, are 
lacking or nonexistent. 
 As a result, there is a huge need for developing new solu-
tions to repair or replace damaged cardiac tissues. Injectable 
hydrogels have emerged as a promising approach for cardiac 
repair in regenerative medicine. [ 4 ] The ability to rely on engi-
neered or regenerated cardiac tissues, instead of a donated 
heart, would be a profound step forward in improving the rates 
of patient survival, as well as furthering the development of 
new treatments for myocardial infarction (MI), and many other 
life-threatening maladies. Further importance of this approach 
arise from the fact that the body’s natural response after MI is 
a process of fi brous remodeling that ultimately leads to scar 
formation instead of functional myocardium formation. [ 2 ] This 
scar formation prevents the heart from functioning properly 
and eventually leads to complete heart failure. Injectable hydro-
gels have the potential to deliver therapeutic agents, cells or 
engineered tissues locally to the damaged area of the heart in 
order to regenerate functional cardiac tissue and, therefore, pro-
vide a revolutionary treatment option for MI. They provide an 
ideal and novel delivery strategy that has the ability to overcome 
the drawbacks associated with current treatments. In recent 
years, numerous injectable hydrogels have been developed and 
many of them have been tried for application in cardiac repair 
after MI. A number of reviews have also been published on the 
subject. However, to date, the clinical application of injectable 
hydrogels in repair or regeneration of post-MI-heart has not 
been realized. 
 In this article, we present a comprehensive overview of var-
ious injectable hydrogels for potential application in cardiac 
repair or regeneration. A brief overview of the pathology of MI 
has been presented in addition to the current clinical treatments 
and their limitations. The suitability of injectable hydrogels for 
cardiac regeneration has been discussed, along with other key 
important factors that need to be considered when designing 
the best hydrogel, the delivery method, and the therapeutics 
to be delivered. Finally, recent advancements in the fi eld have 
been discussed followed by discussions on future perspectives 
for addressing the challenges hindering the widespread clinical 
application of injectable hydrogels in treatment of injured car-
diac tissues. 
 2.  Myocardial Infarction and Cardiac Tissue 
Damage 
 MI can be caused by a number of cardiac pathologies such 
as hypertension, blocked coronary arteries, and valvular heart 
diseases, thereby leading to ischemic cardiac injury. [ 2 ] Death 
of cardiac cells, or myocardial necrosis, can occur as a result 
of insuffi cient blood fl ow which results in reduced supply of 
oxygen to the infarcted tissue. [ 5,6 ] Infarction disrupts the col-
lagen fi ber connections between cardiomyocytes and weakens 
the extracellular matrix which results in thinning and dilation 
of the ventricular wall. Abnormal stresses result in the healthy 
myocardium [ 7 ] in an attempt to counterbalance the reduction in 
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the cardiac function. [ 8 ] This causes changes in the shape, struc-
ture, and functionalities of the heart and stimulates the body 
to respond to these changes and to remodel the injured ven-
tricles [ 2 ] leading to a cascade of consequences. Cytokines and 
growth factors are released to stimulate the immune systems 
in order to clean the infarcted region. [ 2,5 ] Fibroblasts, endothe-
lial cells, and stem/progenitor cells at the infarcted zone each 
play important roles in the formation of granulation tissue, 
which is replaced by the extracellular matrix to form scar tissue. 
The newly generated scar tissue lacks the contractile properties 
needed for the heart to pump blood effi ciently, which subse-
quently leads to heart failure. 
 3.  Available Treatments to Repair Cardiac Damage 
after MI: Motivation for Use of Injectable 
Hydrogels 
 Three available treatments used for the remedy of cardiac tissue 
damage include pharmacological treatments, medical devices 
with interventional therapies including ventricular assist 
devices, and heart transplantation. [ 2,9 ] Medications are used to 
alleviate pain, reduce the cardiac workload and cardiac demand, 
and defend the heart from internally stored toxic substances. 
Medical devices and surgical therapies are used for various 
purposes such as restoring blood fl ow to the heart or reducing 
the generated stress with metallic and drug eluting stents or 
bypass auto grafting. [ 8 ] These devices along with the interven-
tional therapies optimize the functions of remaining viable 
cardiomyocytes, whereas transplantation replaces the damaged 
nonfunctioning tissues. The two techniques, namely, pharma-
cological treatments and medical devices with interventional 
therapies cannot suffi ciently manage the progression of the dis-
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treatment [ 10 ] which replaces the infarcted heart with a healthy 
heart from a donor. [ 11 ] With an increasing number of patients, 
reduced number of donors and the immune complications 
that develop after heart replacement, transplantation remains 
an inadequate and ineffi cient technique. [ 10,12 ] Therefore, new 
methods are needed to tackle the issue more effectively. Car-
diac repair using tissue engineering and regenerative medicine 
appears as a promising solution for cardiac repair after MI. [ 6,13 ] 
 In both tissue engineering and regenerative medicine 
approaches, the repair of the cardiac tissue can be performed 
by transplantation of healthy living cells and/or suitable bio-
materials into damaged cardiac environments. In regenerative 
medicine approach, the appropriate cell types are injected to 
the injured myocardium. These cells can be progenitor cells or 
stem cells that can be differentiated into the necessary cardiac 
cell types [ 5,9 ] or even fully differentiated cardiac cells. In one 
of the approaches of the regenerative medicine, some bioma-
terials-alone can be injected near the infarcted heart tissue to 
provide the mechanical support to the injured heart tissue. In 
tissue engineering, the desired cell types are grown in some 
natural or synthetic biomaterials or sometimes even without 
any biomaterials, for the in vitro formation of cardiac tissue 
that could be implanted around the damaged areas of heart. [ 3 ] 
By using these two techniques, different methodologies can 
be applied including cell delivery, cell-encapsulated hydrogel 
delivery, hydrogels delivery with or without some biomolecules, 
and hydrogel delivery with both cells and biomolecules. [ 9,14–18 ] 
 While in case of cell delivery without hydrogel, the low yield 
of cell retention at the targeted site is a concern, in the case 
of cell encapsulated hydrogel delivery, the hydrogel provides 
a matrix of support for the cells to adhere to prior to being 
injected into the body. Therefore, injectable hydrogels can 
overcome the problems of the lack of cell retention observed 
when cells have been injected by themselves and therefore they 
can produce more effective cardiac regeneration. [ 19 ] In regards 
to delivering biomolecules or drugs, hydrogels can be used to 
encapsulate these substances, and be delivered locally to the tar-
geted sites allowing to control the release kinetics and provide 
optimal sustained release of the molecules such as growth fac-
tors, chemokines and DNA plasmids that promote anti-apop-
tosis, angiogenesis, and endogenous cell recruitment while pre-
venting detrimental systemic effects. [ 7 ] 
 4.  Injectable Hydrogels 
 Hydrogels are “water-swollen polymer networks” [ 7 ] that have 
a high percentage of water content identical to human tis-
sues. They can be injected as a liquid and be crosslinked to a 
gel phase using certain physical or chemical stimuli. Alterna-
tively, they can be injected in a partially crosslinked gel form 
as well. The gel formation after injection allows introducing 
the material inside the body in a minimally invasive way and 
permits the addition of bioactive molecules before the injection. 
Thermo-sensitive hydrogels are specifi cally designed to initiate 
gelation at body temperature. Therefore, once injected, the tran-
sition from liquid to gel can occur. [ 20,21 ] Other methods of in 
situ cross-linking can be photo cross-linking, pH-dependent 
crosslinking, or ionic crosslinking. Some hydrogels exhibit 
structures similar to that of the extracellular matrices, so 
once injected in the defected location, they can enhance the 
formation of a new extracellular matrix and improve integra-
tion within the body. [ 22,23 ] The design parameters during the 
synthesis of hydrogels play an important role in determining 
their properties and behavior. These design parameters need to 
be chosen based on the key properties that the hydrogel must 
exhibit and, therefore, must be ultimately based on the desig-
nated application of the hydrogel. 
 4.1.  Design Parameters in Synthesis of Hydrogels 
 In order to design the optimal hydrogel, there are several 
parameters that need to be considered including the physical, 
material, and biological characteristics. In other words, the 
main factors that are essential to consider in the development 
of hydrogels in tissue engineering are the physical and mate-
rial properties, primarily related to hydrogel mechanics, and 
the biological properties, involved in cell adhesion, for instance. 
Ideally, injectable hydrogels should be biocompatible, biode-
gradable, and bioresorbable to prevent triggering an immune 
response. [ 20 ] The engineered tissue constructs, obtained using 
hydrogel, for cardiac implantation should be vigorous, contract-
ible, and elastic with the ability to sustain periodic contraction 
and relaxation. They should also be well-vascularized so that 
the cells encapsulated in them receive enough nutrients. [ 10,24 ] 
While natural polymers generally present more biocompatible 
features than synthetic polymers, the latter has greater varie-
ties of structure, composition, and properties particularly better 
mechanical properties, which suggests a need for careful con-
sideration of design parameters for the synthesis of hydrogels 
for cardiac applications. [ 25,26 ] 
 While the cross-linking density can be more easily controlled 
in covalently linked hydrogels, the formation of cross-linking in 
ionic cross-linking-based hydrogel is controlled using multiva-
lent counter-ions. [ 27 ] For example, the cross-linking of hydrogels 
in situ with mild temperature fl uctuation in polymerization is 
notably adapted in orthopedic applications. [ 28 ] Maintaining an 
area for tissue growth, adhesion, and gene representation of 
cells is of paramount importance in the design of polymers. 
Scaffolds, cross-linking types, density, and polymer-chain 
rigidity are all important factors for consideration, while evalu-
ating the mechanical properties of hydrogels. [ 29 ] The design of 
the controlled degradation rate of hydrogels should take both 
hydrolysis and enzymatic reactions into consideration. [ 30 ] More-
over, cell–hydrogel interaction contributes to adhesion which 
may be dependent on cell type, receptor–ligand interaction, and 
differentiation. [ 31 ] 
 4.2.  Delivery Routes for Injectable Hydrogels 
 Along with investigating the proper hydrogels, cells, biomol-
ecules, and drugs to promote the greatest amount of cardiac 
repair and regenerations, the optimal delivery pathway must 
also be established. When considering which pathway is the 
best, it is important to consider which methods produce the 
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any route of administration of therapeutics is to have optimal 
amount of active drugs delivered to the target site creating least 
risk to the patient. An important feature of injectable hydrogel 
is that it can be directly injected intramyocardially to the site of 
interest which potentially allows a minimally invasive treatment 
procedure with shorter hospitalization time. 
 Intramyocardial delivery involves injections of drugs or cells 
directly into the myocardium, usually into the left ventricle (LV) 
using an epicardial method or a catheter technique. While epicar-
dial injections are reliable, this approach is invasive, limits access 
to the septum, risks puncturing the LV, and can lead to systemic 
embolization. The catheter-based approach achieves better reten-
tion and avoids local toxicity effects but is also subject to the 
drawbacks of the epicardial method. Intravenous delivery is a 
low-risk procedure and is minimally invasive but shows low cell 
retention and relies profoundly on cell homing. [ 32 ] Intraperito-
neal injections are tough to perform and injection sites are diffi -
cult to monitor. [ 33 ] Disadvantages to nasal systemic drug delivery 
include variable amount of drug absorption, upper airway infec-
tions, and risk of long-term damage to nasal epithelium. [ 34 ] 
 The use of locally injectable hydrogels has clear advantages 
over these other methods. First, the direct placement of mate-
rial to damaged tissue makes the treatment pinpointed. Also, no 
surgery is needed using trans-endocardial methods. Rather, elec-
trophysiological guidance can be used to direct the injections. 
While controlling the amount of injected material is diffi cult and 
cell mortality during injection is inevitable, new strategies have 
been explored to mitigate these shortcomings including vacuum 
stabilization of the treated area. [ 35 ] The feasibility of local injec-
tion methods coupled with the accurate and controlled delivery 
of therapies for damaged tissue makes this a desirable technique 
for MI treatment and requires further investigation. 
 4.3.  Types and Compositions of Injectable Hydrogels 
 Injectable hydrogels can be made from a vast range of biomate-
rials that can be classifi ed as either natural or synthetic in origin. 
Both natural and synthetic biomaterials present strengths and 
weaknesses in terms of biomedical applications that must be 
considered prior to the hydrogel synthesis. They can also be 
divided into two types depending on the type of cross-linking: 
either a chemical cross linking type, linked by covalent bonds 
or a physical cross linking type, physically connected by com-
bining polymeric chains and nanoparticles. [ 20 ] Some of these 
hydrogels both natural and synthetic types are discussed below. 
 4.3.1.  Natural Polymer Based Hydrogels 
 Naturally derived hydrogels are usually biocompatible and sup-
portive of cellular activities. However, they have low mechanical 
strength, may induce an immune response, and are subject to 
batch-to-batch variations. Furthermore, structural modifi cation 
is diffi cult due to their structural fragility and complexity, [ 36 ] 
 Figure  1 a. Despite these drawbacks, naturally derived biomate-
rials continue to be a promising component of hydrogels due 
to their bioactivity and the fact that many of them are naturally 
present in the human body. This correlation can be extremely 
valuable because one of the major goals of hydrogel synthesis is 
to produce tissues that are analogous to the native tissues. The 
characteristics of specifi c natural biomaterials are discussed 
below as well as how these characteristics pertain to injectable 
hydrogels. 
 Collagen : Collagen is a natural polymer; present in the extra-
cellular matrix of skin, bone, tendons, ligaments, and cartilage 
of mammalian tissues, Figure  1 a(i). It is composed of combina-
tions of amino acid sequences that are biocompatible in terms 
of cell recognition and are amenable to enzymatic degradation 
in the presence of collagenases. The advantages of using col-
lagen include its biocompatibility, strong cellular activities, and 
thermal reversibility. The disadvantages of using collagen for 
hydrogel synthesis include its low physical strength or inferior 
mechanical properties, high synthesis cost, and inherent immu-
nogenic responses. In order to improve the physical properties 
of collagens, chemical cross-linking using glutaraldehyde [ 37 ] 
or diphenylphosphorylazide [ 38 ] is recommended. Collagen has 
been widely used as a scaffold for 3D cell cultures and tissue 
engineering of artifi cial skin. The cell–collagen attachment 
mechanisms can be controlled through chemical modifi cation 
by incorporating fi bronectin, chondroitin sulfate, or low levels 
of hyaluronic acid into the collagen matrix. [ 39 ] Collagen has 
been successfully used as a natural polymer based hydrogel 
to repair MI in vivo. Dai et al. investigated the use of collagen 
hydrogels (named Zyderm from INAMED Corp which con-
sisted of 95% collagen type I and 5% of collagen type III) into 
rat MI model. [ 40 ] Results showed improved stroke volume (SV), 
ejection fraction (EF), and wall thickness in collagen hydrogel 
group compared to the controls. The authors claimed that the 
high density and concentration of injected collagen provided the 
benefi cial outcomes, suggesting that collagen hydrogels with 
proper optimization are a promising biomaterial for cardiac 
tissue repair. 
 Gelatin : Gelatin, Figure  1 a(ii), is formed by decomposing 
the collagen triple-helix structure into single strand molecules. 
Furthermore, the preparation of gelatin is distinguished by 
the postbreakage treatment of the collagen structure. Acidic 
treatment yields gelatin of type A, while alkaline treatment, 
characterized by high carboxylic content, yields gelatin of type 
B. [ 41 ] Altering the solution temperature leads to the formation 
of gelatin that is renowned for its high biocompatibility and 
simplicity. Vascularization in tissue engineering is promoted 
through gelatin gels that present growth factors for delivery. [ 41 ] 
Being a natural polymer and a derivative of collagen, gelatin 
also has a high potential for application in cardiac repair after 
MI. 
 Hyaluronic Acid : Hyaluronate, a component of glycosamino-
glycan, is formed into hydrogels by covalent cross-linking with 
hydrazine derivatives [ 42 ] along with the radical polymerization 
of glycidyl methacrylate, [ 43 ] Figure  1 a(iii). Hyaluronidase, a pri-
mary enzyme found in cells and serum, plays roles in degra-
dation of hyaluronate. The application of hyaluronate has been 
investigated in various tissue engineering applications such as 
wound healing and development of engineered skin tissues and 
intradermal implants. [ 44 ] One major disadvantage of hyaluro-
nate, similar to other natural hydrogels, is its weak mechanical 
properties that hinder the scope of its applications. However, 
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molecular structure and composition with various function-
alization. In a recent study, a methacrylated hyaluronic acid 
(MeHA) macromere crosslinked with tetramethylethylenedi-
amine (TEMED) and ammonium persulfate (APS) was applied 
in an MI model to ligate the descending and diagonal coro-
nary artery. [ 45 ] The results showed signifi cantly reduced infarct 
expansion and improved cardiac function. In another study, 
hyaluronic acid was crosslinked with PEG-SH 2 after acryla-
tion and applied as an injectable hydrogel at epicardial surface 
of infarcted site. [ 46 ] It was found that the modifi ed hyaluronic 
acid hydrogel provided a signifi cantly higher EF and SV index 
reduced infarct size, increased wall thickness, and better vessel 
formation compared to those of MI control group, suggesting 
that proper modifi cation and optimization of hyaluronic acid 
hydrogels can offer promising solution for cardiac tissue repair 
after MI. 
 Fibrin : Fibrin gels are formed at ambient temperatures by 
polymerization of fi brinogen with thrombin as a crosslinking 
agent. [ 47 ] Cell-associated enzymatic activity promotes the degra-
dation of fi brin during cell migration, the rate of which is con-
trolled by apronitin, a proteinase inhibitor. [ 48 ] Matrix synthesis 
along with cell migration and proliferation is promoted with 
the use of fi brin gels in a mechanism yielding the incorporation 
of platelet-derived growth factors along with the transforming 
growth factor  I (TGF- I ). [ 49 ] Incorporation of the domain pep-
tides (with a factor XIIIa substrate in one domain and a bioac-
tive peptide containing RGD sequence in another domain) into 
fi brin gels, by the action of transglutaminase during the process 
of coagulation, constitutes the gateway for a variety of neuro-
logical applications of fi brin. [ 50 ] In multi ple studies, injection 
of fi brin into the infarcted area of rat left ventricle resulted in 
increased cell transplant and survival, decreased infarct size, 
www.MaterialsViews.com
www.advancedscience.com
 Figure 1.  Chemical structures of various natural and synthetic hydrogels that have been tried or have the potential for application as injectable hydro-
gels in cardiac tissue regeneration. a) Some natural hydrogels: i) collagen, [ 134 ] ii) gelatine, [ 135 ] iii) hyaluronic acid, [ 135 ] iv) alginate, [ 136 ] v) agarose, [ 137 ] 
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increased blood fl ow to ischemic myocardium, and improved 
cardiac function. [ 51,52 ] Fibrin joins the ranks of hyaluronate 
with its mechanical properties limitations, reducing its scope 
of applications in the tissue-engineering fi eld. Natural wound 
healing and 3D scaffolds for tissue engineering are common 
applications of fi brin. Its properties in cell adhesion along 
with its capability to synthesize from the host’s blood without 
triggering any infl ammatory responses make fi brin highly 
attractive. 
 Alginate : Alginate, also known as alginic acid or algin, 
hydrogels are anionic polysaccharides, extracted from the 
cell walls of a brown algae. They are primarily used in drug 
delivery for wound healing, due to their high biocompatibility, 
low cost, and simple gelation with Ca 2+ , Mg 2+ , Ba 2+ , and Sr 2+ , [ 53 ] 
Figure  1 a(iv). The transplantation of chondrocytes, hepato-
cytes, and islets of Langerhans has been used with alginate 
gel beads. [ 54 ] One main disadvantage of alginate hydrogel is 
its release of divalent ions to surrounding, resulting in lim-
ited long-term stability. This mechanism can be counteracted 
with covalent cross-linking using a variety of molecules which 
produce different cross-linking densities. [ 30 ] Another solu-
tion involves the isolation of polyguluronate blocks from algi-
nate and subsequent oxidation and covalent cross-linking of 
these derivatives with adipic acid dihydrazide. [ 30 ] Oxidization 
of alginate leads to its degradation in aqueous media with 
temperature and pH being control factors. [ 55 ] The hydrophi-
licity of alginate constitutes a disadvantage in terms of protein 
absorption. However, ligand-specifi c binding properties can 
be enhanced by modifying with lectin or other ligands. When 
covalently coupled with an RGD containing cell adhesion 
ligand, the adhesion and proliferation of differentiated pheno-
types of skeletal muscle cells were signifi cantly enhanced. [ 56 ] 
Alginate hydrogel has also been tested in cardiac applications 
for treatment after MI, due to its nonthrombogenic proper-
ties. [ 57,58 ] In another study, a calcium crosslinked alginate 
hydrogel was tested in rat MI model and was found to be sig-
nifi cantly effective in reducing left ventricular (LV) expansion 
and increasing the old-infarcted heart wall thickness. [ 59 ] Simi-
larly, alginate also showed promising results in large animal 
models such as a porcine model for treatment of MI. [ 60 ] Con-
sequently, alginate has become the very fi rst injectable mate-
rial to enter clinical trials for the treatment of MI ( Ikara Hold-
ings, Inc. IK-5001 for the Prevention of Remodeling of the Ventricle 
and Congestive Heart Failure After Acute Myocardial Infarction. 
NCT01226563; 2010 ). 
 Agarose : Agarose, Figure  1 a(v), like alginate, is a marine 
extracted algal polysaccharide except that it can form thermally 
reversible gels in a structure composed of double-helices and 
junction zones consisting of multiple chain aggregations. [ 61 ] 
Modifying the physical structure of agarose by controlling the 
concentration can alter the pore size of the gel. By combining 
the properties of large pores and minimal stiffness at low con-
centrations cell migration and proliferation can be enhanced. [ 61 ] 
For an enhanced cell interaction mechanism, cell adhesion 
peptides (CDPGYIGSR) have also been covalently coupled with 
agarose. [ 62 ] In a recent study, agarose was used for encapsulation 
of cardiac stem cells (CSCs) and their delivery to an infarcted 
heart which resulted in enhanced cardiac repair and blood vessel 
formation. [ 63 ] 
 Chitosan : Chitosan hydrogel is prepared by  N -deacetylation 
of chitin and is characterized by high biocompatibility and low 
toxicity due to its structural similarity to natural glycosamino-
glycans, Figure  1 a(vi). In addition, its solubility in an acidic 
environment, due to its high crystallinity, makes the application 
of chitosan highly effective. The hydrogel formation process 
of chitosan is performed by ionic [ 64 ] crosslinking or chemical 
cross-linking with glutaraldehyde. Chitosan modifi cation with 
sugar residues [ 65 ] and proteins such as collagen and albumin 
have yielded promising results in tissue-engineering. [ 66 ] Chi-
tosan-based hydrogels can be used to protect the transplanted 
cells, promote angiogenesis, reduce infarct size, and improve 
cardiac function due to their ability to conjugate with various 
bioactive molecules. This can increase their bioactive func-
tions without affecting their physical/chemical properties, 
such as gelation behaviors, swelling and degradation charac-
teristics, network structure, and mechanical strength. [ 67 ] In 
a recent study, Lu et al. used chitosan with β-glycerol phos-
phate and hydroxyethyl cellulose to synthesize a temperature-
sensitive hydrogel and applied in a rat MI model. [ 68 ] A signifi -
cant improvement was found in infarct size, wall thickness, 
microvessel, end systolic diameter (ESD), and end diastolic 
diameter (EDD). Two other independent studies also reported 
similar results for the thermo-responsive chitosan hydrogel in 
rat MI model, demonstrating its high effectiveness in cardiac 
tissue repair. [ 69,70 ] 
 Keratin : Keratin, Figure  1 a(vii), represents a broad category 
of fi brous structural proteins that make up human skin, hair, 
and nails. Monomerically, keratin forms intermediate fi la-
ments which subsequently form these macrostructures. Keratin 
has the ability to self-assemble into fi brous scaffolds. [ 71 ] This 
creates an ideal matrix allowing for cellular permeation and 
proliferation. The wide availability of keratin makes it a desir-
able natural resource of biomaterials. More than 30 different 
cytokines and factors residual from hair morphogenesis might 
be useful in cardiac repair, augmenting myocyte cell viability, 
migration, and gene expression. [ 72 ] Three of these factors, 
namely, NGF, TGF- β1, and BMP4, were found to support 
angiogenesis. Also, keratin injections showed no evidence of 
infl ammation, and keratin-based scaffolds were found to regen-
erate nerve function and foster neuromuscular recovery. [ 71 ] 
Hydrogels made from keratin are notably biocompatible, have 
the proclivity to self-assemble, and effi ciently integrate into 
environments. 
 Matrigel : Matrigel is a gelatinous protein mixture, secreted 
by Engelbreth–Holm–Swarm (EHS) mouse sarcoma cells, and 
commercially available under different trade names marketed 
by multiple companies. It is usually used as substrate coating 
to improve cell adhesion; however, it can also be used as an 
injectable hydrogel for cardiac repair. Kofi dis et al. employed 
matrigel for delivery of embryonic stem cells to an infarcted 
myocardium, where the cells were encapsulated in the matrigel 
injected in the infarcted left ventricle. [ 73,74 ] Their study proved 
that injectable matrigel may help in fi xing the heart’s shape, 
geometry, and functionality [ 74 ] after MI. Similarly, Zhang et 
al. showed that a mixture of collagen, matrigel, and cells as a 
source of cardiomyocytes offered the same functionalities once 
injected in vitro, as Kofi dis and his colleagues demonstrated in 
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death and enhance vascularization after being introduced to the 
infarcted region. [ 76 ] 
 Decellularized ECM : In order to better mimic the composi-
tion of the native cellular microenvironment a number of groups 
have investigated the use of hydrogels from decellularized tis-
sues or extracellular matrices (ECMs). ECM hydrogels replicate 
the native cellular microenvironment with specifi c character-
istics based on the tissue from which they are extracted. They 
can provide polymeric hydrogels with native chemical and bio-
physical cues and therefore improve the attachment, survival 
and function of the transplanted cells. Besides, each tissue has a 
distinct composition of fi brous proteins, proteoglycans, and gly-
cosaminoglycans that make up its ECM. [ 77 ] Recent studies have 
shown that ECM hydrogels made from decellularized cardiac tis-
sues can help in repairing scarred myocardium after MI. Injec-
tion of ECM hydrogel from the myocardial matrix, into rats LV 
showed no embolization or ischemia, and no adverse effect on 
neighboring tissues or cardiac rhythm. [ 78 ] Additionally, when the 
interaction with human blood was evaluated, the decellularized 
matrix had no adverse effect on activated partial thromboplastin 
time or prothrombin time across different blood concentrations, 
verifying its hemocompatibility. 
 4.3.2.  Synthetic Hydrogels 
 Synthetic hydrogels are of particular interest in cardiac repair 
and other tissue engineering applications due to their strong 
mechanical properties and easily controllable features, [ 79 ] 
Figure  1 b. Here, we discuss various synthetic hydrogels which 
have been used in tissue engineering or regenerative medicine 
and have potential for application in cardiac repair. 
 Poly(acrylic acid) Derivatives : Poly-acrylic acid (PAA), Figure 
 1 b(i), has several derivatives that are used as biomaterials. Poly-
2-hydroxyethyl methacrylate, also known as poly-HEMA, is 
hydrolytically stable. The cross-linking mediator can predict its 
permeability and hydrophilicity. The disadvantage of PAA-deriv-
atives is that they are not completely biodegradable. [ 4 ] A dex-
tran-modifi ed poly-HEMA has been developed that is found to 
be degradable by specifi c enzymes. Attaching the poly-HEMA 
to oligo- D -lactide to form a gel phase of the poly-HEMA without 
using lethal chemicals, have also been reported. [ 80 ] 
 Another important derivative of PAA, worth mentioning, is 
poly- N -isopropyl-acrylamide, or PNIPAAm, which is commonly 
used in tissue engineering for its temperature-dependent 
biphasic behavior. It can change its phase from liquid to gel-
phase above its lower critical solution temperature (32 °C in 
water). Thus, it can be injected into the body as a prepolymer 
solution which can turn to a gel-like phase at body temperature 
after injection, [ 4 ] which makes this polymer advantageous. The 
transition depends only on the body’s temperature and is not 
based on a specifi c timing which makes them even more ben-
efi cial. On the other hand, these polymers are nondegradable 
and may be toxic, teratogenic, and/or carcinogenic. [ 4 ] In an 
earlier study, a biodegradable PNIPAAm hydrogel was injected 
in infarct heart and was found to result in improvement of 
heart function. [ 81 ] Similarly, in another report, PNIPAAm with 
a growth factor and antioxidants showed signifi cant enhance-
ment of MSC growth within the hydrogel providing a suitable 
microenvironment for heart cells to function. [ 82 ] Although the 
synthetic poly(acrylic acid) derivatives have promising potential 
for application in the treatment of cardiac tissue damage, their 
biocompatibility and infl ammatory response may arise which 
are needed to be resolved for their extensive application in the 
future. 
 Polyethylene Glycol or Polyethylene Oxide and Copoly-
mers : Polyethylene glycol (PEG) or polyethylene oxide (PEO), 
Figure  1 b(ii), is a biocompatible and hydrophilic polymer 
which is also FDA approved for several biomedical applica-
tions. PEG is specifi cally used to prepare biological conju-
gates, [ 83 ] modify surfaces, [ 84 ] and stimulate cell membrane 
synthesis. [ 4 ] It does not cause immune responses and has 
low cell adhesion and protein binding. [ 85,86 ] It is produced 
from the ionic polymerization of ethylene oxide and has end 
hydroxyl groups that facilitate the formation of PEG mac-
romers which in turn contribute to its chain polymerization. 
The PEG macromers can be injected in the injured sites 
because of their low toxicity. PEG in its gel phase is usu-
ally used as a scaffold and it is coated to inhibit interactions 
between encapsulated cells and the poly mer itself. [ 87–90 ] The 
gel phase can be manufactured via UV photo-polymerization 
of the polyethylene oxide with acrylate ends in the presence of 
R-hydroxy acid. [ 91 ] When interaction with proteins is needed, 
the hydrogel can be reinforced with bioactive peptides [ 3 ] a 
property required for biomaterials used in tissue engineering 
and regenerative medicine. [ 92 ] 
 In addition, copolymers of the PEG have been found to be 
useful in drug delivery. [ 93,94 ] For example, PEG-PPO-PEG is an 
interesting triblock copolymer made of PEG and poly propylene 
oxide (PPO) which is a thermo-sensitive polymer that can 
change to a gel phase at body temperature. [ 95 ] The drawback is 
that it is not biodegradable. To overcome this issue, a diblock (or 
triblock) of PEG and polylactic acid (PLA) was developed based 
on the knowledge that the PLA is biodegradable and harm-
less. [ 96 ] In an earlier study, PEG was used for understanding 
the cardiomyocytes–matrix interactions in a 3D microenviron-
ment. The results showed an increase in viability and func-
tionality of encapsulated cardiomyocytes. [ 97 ] In another study, 
the embryonic stem cells (ESCs)-encapsulated PEG hydrogels 
demonstrated ESCs differentiation to the cardiomyocytes lin-
eage and the cells showed cardiac-like activity. [ 98 ] Wang et al. 
injected bone marrow-derived MSC-encapsulated PEG-PCL-
PEG copoly mer mixed with cyclodextrin in the MI region of a 
rabbit heart and observed formation of dense vessel network at 
the infarct site with signifi cantly reduced cardiac infarction. [ 99 ] 
All of these studies demonstrated the superior activities of PEG 
copolymers in the treatment of MI. 
 Polyvinyl Alcohol : Polyvinyl alcohol, Figure  1 b(iii), or PVA, 
is produced through the hydrolysis of polyvinyl acetate. The 
PVA hydrogel is developed using either physical or chem-
ical cross-linking. Chemical cross-linking can potentially be 
harmful, so some recent studies have focused on replacing 
the chemical cross-linking with photocrosslinking. The solu-
bility and hydrophilicity of manufactured hydrogel depend on 
the molecular weight and the degree of hydrolysis. PVA can 
connect to multiple biological molecules. [ 3,4 ] It can be used as 
a matrix due to its elasticity and role in improving the diffu-
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consequently its adhesion properties are relatively minimal 
but can be enhanced by mixing it with biological factors. PVA 
hydrogel has strong mechanical properties and a low rubbing 
coeffi cient. [ 3 ] All these excellent properties of PVA exhibit prom-
ising tissue engineering applications, especially cardiac tissue 
repair. 
 Polyphosphazene : Polyphosphazene, Figure  1 b(iv), has 
attracted scientists’ interest because of its biodegradability. By 
modifying its side-chain organization the dynamics behind its 
degradation process can be regulated. The polyphosphazene 
polymer includes interchanging atoms of phosphorus and 
nitrogen and two side groups connected to each phosphorus 
atom. A transitional product, poly-dichlorophosphazene, is 
formed before creating the fi nal polymer. The gel phase of the 
end product, polyphosphazene, is a result of its hydrophilic 
backbone and its fl exibility acquired following different sub-
stitution reactions. It can only be modifi ed to create a thermo-
responsive hydrogel. From the polyphosphazenes, nonionic and 
ionic hydrogels can be prepared. The latter reacts with variation 
in pH or ionic strength and consequently they might be useful 
for protein drug delivery. [ 4 ] 
 Polypeptides : Peptides, Figure  1 b(v) can form nanofi ber 
hydrogels by means of charge interactions, hydrogen bonding, 
and other interactions. [ 100 ] The use of peptides is very benefi -
cial since they can act as a scaffold that mimics a natural extra-
cellular matrix (ECM). [ 101 ] Different types of peptide hydro-
gels can be formed. Thermo-responsive peptide hydrogels 
have been made of elastin-like proteins that contain tropoe-
lastin. [ 102,103 ] The ion-induced cross-linked peptide hydrogels 
change to a gel-like structure based on interactions with a con-
centration of salt, which will increase the ion strength, specifi -
cally by minimizing the repulsion occurring in the positively 
charged side-chain. [ 104 ] Some peptides can form pH-responsive 
hydrogels. Two amino acids are essentially responsible for this 
activity: valine and lysine. In liquid phase, hydrophobic valine 
and hydrophilic lysine are on opposite sides of the peptide’s 
secondary structure and this combination creates hydrogen 
bonds within the structure. As the pH decreases, the valine 
and adjacent lysine repel each other. As a result, the peptide 
structure unfolds and the hydrogel dissolves. Some peptides 
upon being attached to the fl uorenyl-methoxy-carbonyl can 
form a gel-like hydrogel with enhanced cell adhesion and pro-
liferation properties. [ 79 ] 
 4.3.3.  Composite Hydrogels 
 In addition to various natural and synthetic polymer-based 
hydrogels, a number of hybrid and composite hydrogels have 
also been tried for application in cardiac repair. Some specifi c 
examples include ECM-fi brin hydrogels, [ 105 ] alginate-chitosan 
hydrogels, [ 106 ] and ECM-polyethylene glycol hydrogels. [ 107 ] 
Due to the benefi ts of both fi brin and alginate as biomate-
rials for injectable hydrogels, a composite of these materials 
was used for cardiac repair after MI. Results showed that the 
expansion of the infarcted region of the left ventricle stopped 
upon injection of the hydrogel. Additionally, myocardial 
stiffness was relatively higher than those of control groups 
and fi brous collagen in the myocardium border region was 
increased. [ 108 ] Hence, the soluble collagen content in the 
infarcted zone was decreased, which accounts for the decel-
eration of damaged tissue enlargement. Thus, injection of 
fi brin-alginate as well as other suitable composite hydrogels 
may provide an effective treatment to suppress the expansion 
of infarcted tissue. 
 A recent strategy for achieving multiple functionalities in 
hydrogels is to incorporate various nanoparticles in them, 
thereby developing nanocomposite hydrogels. The nanoparti-
cles to be incorporated can be polymeric, metallic, ceramic, 
inorganic, or carbon-based as shown in  Figure  2 a [ 109 ] while 
the strategies of incorporation can be physical entrapment, 
noncovalent immobilization, or covalent immobilization 
as shown in Figure  2 b. [ 110 ] The different strategies for the 
delivery of injectable composite hydrogels as well as other 
injectable hydrogels including acellular hydrogel alone, acel-
lular hydrogel with some biomolecules, and the cell-laden 
hydrogel delivery are shown in Figure  2 c. [ 76 ] Recent advances 
in the applications of these hydrogels in cardiac repair and 
regeneration with specifi c examples are discussed in the sec-
tion below. 
 5.  Recent Advances in Application of Injectable 
Hydrogels in Cardiac Tissue Repair 
 While numerous hydrogels have been synthesized for tissue 
engineering, only a few of them have been tested for cardiac 
applications. However, some of these hydrogels have shown 
strong promises in enhancing the repair of infarcted myocar-
dium. Acellular injectable hydrogels without any therapeutic 
biomolecules were found to thicken the myocardial wall, 
thereby reducing abnormal stresses when injected directly 
after an infarction. [ 7,13 ] Other reported improvements were 
enhanced cardiac function, reduced infarct size, and induced 
neovascularization, using injectable hydrogels as carriers for 
various biomolecules [ 111 ] and as carriers of cells. [ 13,77,112–114 ] In 
subsequent sections, we discuss the recent advances in applica-
tions of injectable hydrogels in cardiac tissue repair. 
 5.1.  Acellular Hydrogels for Treatment of MI 
 As mentioned earlier, acellular hydrogels have exhibited prom-
ising results in cardiac repair as both a bulking agent to pro-
vide mechanical support to the infarcted heart when injected 
alone, and as a carrier for various biomolecules including 
growth factors, cytokines, and DNA plasmids. Several sci-
entists have also focused on acellular biomimetic hydrogels 
without biomolecules in order to focus on materials that give 
the proper biological and chemical cues that mimic the native 
microenvironment. For example, in a recent study, an inject-
able ECM hydrogel derived from decellularized porcine myo-
cardial tissue was used to reverse the negative remodeling 
process in infarcted myocardial tissue. [ 78 ] Upon injecting the 
hydrogel into infarcted pig hearts, the tissue self-assembled 
into a porous scaffold, allowing cell infi ltration. Histological 
characterization showed that the hearts that were injected with 
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while the control group exhibited a fi brillary layer and the 
saline-injected control endocardium was moderately thickened, 
 Figure  3 a–c. ECM hydrogel-treated myocardial tissue exhibited 
10% less collagen content compared to control groups, as well 
as the presence of cardiomyocytes as evidenced by cardiac 
troponin-T staining, Figure  3 d. This reduction in fi brosis is 
essential for heart repair since fi brous tissue is noncontractile, 
which inhibits the heart’s ability to pump blood properly. The 
tissue injected with the ECM hydrogel showed foci of neovas-
cularization as well, whereas the control groups did not, Figure 
 3 g,h. This observation provided evidence of cardiac regenera-
tion due to the fact that blood fl ow to the infarct zone provides 
oxygen essential for cardiomyocytes to grow. 
 Rodents were used to assess the biocompatibility and degra-
dation properties of the myocardial ECM hydrogel, Figure  3 i. 
The ECM hydrogel exhibited complete degradation by 28 d 
postoperation. The group receiving nondecellularized porcine 
myocardial matrix (NDM) also showed similar degradation 
in addition to an immune response exhibited by infl amma-
tion and multinucleated giant cells. This further confi rms 
that the ECM itself does not elicit an immune response, 
as long as the matrix is successfully decellularized. These 
positive results provide a base of support to move this ECM 
hydrogel toward clinical studies. The detailed study elicits 




 Figure 2.  Schematic representation of nanoparticle loaded injectable composite hydrogels, and delivery of various hydrogels including acellular 
hydrogels alone, acellular hydrogels with various biomolecules and hydrogels with various cells. a) A range of nanoparticles such as polymeric nano-
particles, metallic-metal oxide based nanoparticles, inorganic nanoparticles, and carbon-based nanomaterials can be incorporated in hydrogels to make 
nanocomposite hydrogels. Adapted with permission. [ 109 ] b) The common strategies for incorporation of nanoparticles in hydrogels: i) stabilization of 
inorganic or polymeric nanoparticles by nano–micro-sized hydrogel particles, ii) noncovalently immobilized nanoparticles in a hydrogel matrix, and iii) 
covalently immobilized nanoparticles in hydrogel matrix. Adapted with permission. [ 110 ] c) Different strategies of injectable hydrogel delivery for treat-
ment of MI. The injectable hydrogels can be delivered alone without any biomolecules or cells, with some biomolecules as carriers or with cells as a 
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 5.2.  Injectable Cell-Laden Hydrogels for Car-
diac Repair 
 Various injectable hydrogels, including 
tetronic-fi brinogen (TF) and PEG-fi brinogen 
(PF) conjugate hydrogels, have been used to 
enhance the effi cacy of stem cell delivery in 
infarcted myocardium, [ 13,112–114 ]  Figure  4 a,b. 
In one study, a left thoracotomy was per-
formed by antero-lateral incision, followed by 
the injection of hydrogel precursor solution 
on four sides of the infarcted region. [ 13,77 ] UV 
light was used to catalyze the crosslinking 
process. [ 13 ] Results showed that hydrogel 
treatment to the left ventricle (LV) led to an 
increase in wall thickness, which in turn 
increased the survival of viable cardiac tissue 
where infarction took place. [ 115,116 ] Remod-
eling of the LV was revealed to some extent 
via echocardiography. The prevention of LV 
dilation and fractional shortening deteriora-
tion were observed in addition to minimal 
wall thinning. [ 23 ] Both cross-linked PF and 
TE hydrogels with BMNCs showed increased 
neovascularization, leading to improvements 
in cardiac function. Injecting TF hydrogel 
and saline led to the same arteriole density, 
while PF 2% exceled the former by offering 
a greater restoration of heart function and 
neovascularization. [ 13,117 ] 
 In another study, bone marrow derived 
stem cells (BMSCs) from rabbit tibia were 
encapsulated in Dex-PCL-HEMA/PNIPAAm 
hydrogels and injected into their infarcted 
myocardium after performing left thora-
cotomy and ligating the left coronary artery. 
One month later, the percent infarcted size 
was obtained from the ratio of infarcted 
wall to all the surface area of left ventricle 
(LV). [ 77,118 ] The BMMNCs survived up to 
3 d in hydrogel. Notably, the cell density in 
the animal group injected with cell-laden 
hydrogel was much higher compared to that 
in the groups with either cells or hydrogels 
alone. After 48 h there was no signifi cant 
difference in the results between the four 
groups on the level of LV end-systolic dia-
meter (LVESD), LV end diastolic diameter 
(LVEDD), and LV ejection fraction (LVEF). 
However, the echocardiography results after 
30 d demonstrated that LVEF of the group 
www.MaterialsViews.com
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 Figure 3.  a–h) Enhancement of cardiac muscle and reduction of infarct fi brosis using myocar-
dial matrix. Histological characterization of infarcted pig hearts: Masson’s trichrome staining 
images are representative of six matrix-injected pigs and four control animals. a) Matrix-
injected hearts had a distinct, thick endocardium (red stained muscle, indicated with an 
asterisk). b) Noninjected control animals had a loose fi brillar layer (blue) beneath the endothe-
lium. c) In saline injected control animals, the endocardium was moderately thickened with 
minimal muscle (red). d) An adjacent tissue section for the matrix-injected animal in a) stained 
for cardiac troponin-T, indicating the presence of cardiomyocytes. e) Area of endocardial layer 
of muscle as a proportion of the infarct. f) Percentage of collagen content in the infarcts. Data 
are means ± SEM and were obtained from Masson’s trichrome slides a–c). * P < 0.05 (Stu-
dent’s t test). g,h) Matrix-injected hearts contained foci of neovascularization in the area below 
the endocardium (g, arrows), but none of the saline or noninjected control hearts showed 
these areas of neovascularization h). Scale bar, 200 mm. i) Myocardial matrix is biocom-
patible and biodegradable. Representative histological sections of cell infi ltration in matrix-
injected rat hearts injected with saline, PMM, or NDM at days 3 , 14 , and 28. Infl ammation 
and multinucleated giant cells are present in the 
NDM groups at days 14 and 28 (arrows). The PMM 
(asterisk marked porous network) was completely 
degraded by 28 d. Scale bar, 200 mm. Reproduced 
with permission. [ 78 ] Copyright 2013, American Asso-
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 Figure 4.  Arterial staining and histological morphology of excised rat hearts treated with injected hydrogels 4 weeks post MI. Image (a) shows Alpha-
SMA positive vessels in the infarct and peri-infarct zones, 4 weeks after MI. Panels (i) and (ii) show control (saline injection) peri-infarct and infarct 
zone respectively, (iii) and (iv) show peri-infarct and infarct treated with PF1%, (v) and (vi) show those treated with PF2% respectively, (vii) and (viii) 
treated with TF1%, respectively, and (ix) and (x) treated with TF2%, respectively. In image (b) 4 weeks after the MI the treated rat hearts were cut 
into equal transverse slices to show the gross appearance and histological morphology (i) in that of the untreated saline control group where saline 
injection was only used. The PF1% hydrogel injection in (ii), the PF2% hydrogel injection in (iii), the TF1% hydrogel injection in (iv), and the TF2% 
hydrogel injection in (v). Reproduced with permission. [ 13 ] Copyright 2014, Elsevier. Image (c) shows immune-histochemical staining for the smooth 
muscles for the four groups 30 d after MI. Panel (i) shows the control group, (ii) shows hydrogel group, (iii) shows BMMNC group, and (iv) shows 
BMMNC + hydrogel group. Reproduced with permission. [ 124 ] Image (d) shows the staining with Masson trichrome of the infarcted wall forcollagen 
(green) and muscle (red) of the four groups. (i) PBS-only group of the four groups; (ii) OPF-only group; (iii) PBS + ESC group; and (iv) OPF + ESC 
group. Reproduced with permission. [ 19 ] Copyright 2014, Elsevier. Image (e) also shows staining with Masson’s trichrome of the infarct area and shows 
similar level of tissue improvement with BADSCs treatment alone or Chitosan alone compared to the control group with Chitosan hydrogel delivery of 
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that received BMMNCs encapsulated in the hydrogel was more 
signifi cant than the other groups. In contrast, this group had 
lower levels in LVEDD and LVESD. Thus, the injected hydro-
gels enriched with encapsulated cells increased cell engraft-
ment, where hydrogel could serve as the ECM, leading to an 
improved rate of cell retention and survival in the infarcted 
zone. [ 77,119,120 ] 
 In a third study, embryonic stem cells (ESCs) extracted from 
mice were encapsulated into an oligo [poly(ethylene glycol) 
furmarate] (OPF) hydrogel and injected at the border of the 
infarcted region 1 week after inducing MI in mouse hearts. 
After 24 h, the hearts were excised, frozen and bisected into 
fi ve different sections, followed by tracing Green Fluorescent 
Protein (GFP)-labeled mouse ESCs via fl uorescent microscope. 
After 4 weeks, immunochemical staining was used to deter-
mine graft size in the specimens. [ 19 ] 
 The synergistic effect of OPF hydrogel and ESCs was evident 
by the fact that ESCs in OFP differentiated into cardiomyo-
cytes, ESC count was higher, the ESCs were aggregated in the 
hydrogel, LV function for mice with ESC and OPF showed the 
most improvement, infarction size diminished the most, col-
lagen deposition was minimal, no signs of prolonged infl am-
matory response were observed, as well as a signifi cant increase 
in neovascularization was exhibited. Also, the OPF hydrogel 
completely degraded. [ 19,121–123 ] 
 In a recent study, cardiac progenitor cells (CPC) were found 
to exist in the form of a CD29 positive population. [ 124 ] Chi-
tosan hydrogel was tested with incorporation of these cells as a 
method to repair damaged myocardium. CD29+ brown adipose 
derived stem cells (BADSCs) were obtained from rats, and then 
rats were subdivided into four groups containing 20 rats each. 
Each group received one of the following treatments: PBS only, 
chitosan hydrogel, BADSCs only, and BADSCs encapsulated in 
chitosan hydrogel. These treatment groups were put into place 
after the left coronary artery was ligated. [ 124 ] Lateral investiga-
tions were conducted to identify the cardiac differentiation of 
BADSCs in vitro, where they were treated with and without chi-
tosan, Figure  4 e. As a result, the treated groups showed signifi -
cant favorable results. In detail, the cross-linked strained myo-
fi laments were better organized than the control group. Anal-
ysis showed signifi cant increase in the levels of collagen 1 when 
using chitosan treated with BADSCs compared to the control 
group. In addition, applying chitosan hydrogel led to enhance-
ment in cell retention in the infarcted site, leading to survival of 
the grafted cell in ischemic myocardium. [ 124 ] 
 Furthermore, chitosan + BADSCs had a synergistic effect 
as they led to a signifi cant recovery of cardiac function—sig-
nifi cant reduction took place in the left ventricle infracted zone, 
which led to a marked increase in the number of cells respon-
sible for cardiomyocytes differentiation, as well as neovascular 
formation. [ 124 ] 
 These studies clearly demonstrate how encapsulating cells in 
hydrogels can increase their therapeutic effi cacy in terms of pos-
itive cardiac remodeling. The material properties of the hydrogel 
can be tailored specifi cally to provide the cell source with the 
correct chemical, mechanical, and biological signals to differen-
tiate into the desired lineage, such as cardiomyocytes. Further-
more, hydrogels provide the cells with a mechanically stable, 
biocompatible environment to protect the cells from being 
washed away by the body’s defense mechanisms. Therefore, 
these tunable properties give hydrogels great potential to be an 
integral part of the success of cell therapy in treating myocardial 
infarction. 
 5.3.  Carbon Nanotube-Embedded GelMA Hydrogels for Cardiac 
Constructs 
 In the case of engineering heart tissue, scaffolds do not usually 
exhibit the capability to conduct electrical current. However, the 
native tissue contains purkinje fi bers that do in fact conduct 
electricity, allowing the heart to beat. A recent study employed 
carbon nanotubes (CNT) embedded GelMA hydrogel with 
improved mechanical and electrical properties to enhance the 
differentiation of the mesenchymal stem cells (MSCs) into car-
diac cells,  Figure  5 . Another recent study showed a promising 
approach for high-performance cardiac scaffold materials that 
can be created with the incorporation of CNTs into a photo-
cross-linkable GelMA hydrogel. [ 125 ] The cardiac cells in CNT-
GelMA were observed to be in an elongated state and F-actin 
fi bers were demonstrated to be intact and more homogeneous 
in comparison with pristine GelMA. Immunostaining showed a 
signifi cant increase in both sarcomeric α-actinin and Troponin 
I on the CNT-GelMA in comparison with the pristine GelMA. 
Also, sarcomere alignment, sarcomere interconnected struc-
tures, and troponin aggregation were observed on the CNT-
GelMA. Both CNT-GelMA and pristine GelMA can generate 
synchronous beating activity. However, after the spontaneous 
beating rates were recorded over a 6 d period, the CNT-GelMA 
showed a beating rate average that was both more stable and 
three times greater than the pristine GelMA. In order to study 
the cardiac beating, two model drugs known for disrupting the 
biological processes necessary for continued heart beats were 
introduced: heptanol and doxorubicin. In the case of heptanol, 
the gap-junctional beating propagation is inhibited in the 
heart. However, in the CNT-GelMA, synchronous beating was 
observed even after the drug was administered. In fact, it took 
40–65 min for synchronous beating to stop in the CNT-GelMA, 
as opposed to only 20 min in the pristine GelMA. This demon-
strated that the CNT in the hydrogel assisted in maintaining 
the pathway that the heptanol disables and enhanced beating 
amplitudes and rates. [ 125 ] 
 5.4.  Injectable Hydrogel-Based Gene Delivery Systems 
 Gene therapy offers a unique opportunity to promote local 
healing of damaged myocardial tissue mainly by promoting 
new blood vessel formation and attenuating fi brosis. Some 
methods that are frequently used in delivering specifi c thera-
peutic genes using injectable hydrogels include upregulating or 
knocking down specifi c host genes or simply by overexpressing 
certain genes of therapeutic interest. One recent study aimed 
to improve the biofunctionality of injectable hydrogels by incor-
porating a gene delivery system using polyethylenimine (PEI) 
functionalized graphene oxide nanosheets (fGO) complexed 
with vascular endothelial growth factor-165 (VEGF), all incorpo-
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 Figure 5.  a–d) Structural, physical, and electrical properties of CNT-GelMA hydrogels: a) schematic diagram illustrating the isolated heart conduction 
systems showing the purkinje fi bers, which are located in the inner ventricular walls of the heart. b) Preparation procedure of fractal-like CNT networks 
embedded in GelMA hydrogel. c) TEM image of GelMA-coated CNTs. d) SEM images show porous surfaces of a 1 mg mL −1 CNT-GelMA thin fi lm. 
e,f) Adhesion, maturation, alignment, and phenotype of cardiac cells on CNT-GelMA hydrogels. e) Confocal images of cardiomyocytes after culturing 
for 5 d on pristine GelMA and 1 mg mL −1 CNT-GelMA revealed more uniform cell distribution and partial cell alignment on CNT-GelMA. Higher 
magnifi cation images showed well-elongated cardiac cells and well-developed F-actin cross-striations (bottom right, white arrows) on CNT-GelMA 
but not on pristine GelMA (bottom left). f) Immunostaining of sarcomeric R-actinin (green), nuclei (blue), and Cx-43 (red) revealed that cardiac tis-
sues (8 d culture) on (i) pristine GelMA and (ii) CNT GelMA were phenotypically different. Partial uniaxial sarcomere alignment and interconnected 
sarcomeric structure with robust intercellular junctions were observed on CNT-GelMA. Immunostaining of Troponin I (green) and nuclei (blue) 
showed much less and more aggregated Troponin I presence on (iii) pristine GelMA than on (iv) CNT-GelMA. g–i) Improved mechanical integrity and 
advanced electrophysiological functions of cardiac tissues on CNT-GelMA. g) Spontaneous beating rates of cardiac tissues recorded from day 3 to day 
9 on a daily basis. h) CNTs protected cardiac tissues against damages by heptanol. Plots of spontaneous beating amplitude over time (5 d culture) for 
0–5 mg mL −1 CNTs in GelMA in response to 4 × 10 −3  M heptanol. i) Time lapse before sporadic beating and stop of beating induced by heptanol 
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 Figure 6.  Injectable hydrogels for gene delivery applications. a) Photocrosslinkable hydrogel for myocardial delivery of vascular endothelial growth 
factor (VEGF) carrying gene using cationic functionalized graphene oxide (fGO) nanoparticles. Schematic of stepwise formulation process for direct 
intramyocardial injection of damaged heart with acute myocardial infarction. Reproduced with permission. [ 126 ] Copyright 2014, American Chemical 
Society. b) Delivery of siRNA using biopolymer hydrogel—schematic of hydrogel formation for delivery of siRNA and subsequent inhibition of gene 
expression in incorporated and neighboring cells. Biomaterial solutions of alginate, photo alginate, or collagen are mixed with siRNA and GFP-positive 
cells, and hydrogels are then formed by crosslinking, photo-crosslinking, or thermos-gelling, respectively. The siRNA diffuses through the hydrogel to 
affect incorporated cells, and it is also released from the hydrogel to locally affect surrounding cells that are part of the host tissue. Reproduced with 
permission. [ 127 ] Copyright 2009, American Chemical Society. c) Hydrogel for delivery of recombinant viruses using nanohybrid complexes. Controlled 
release of baculovirus (Bac) using CNT reinforced hydrogel. TEM images of (i) nonfunctionalized CNT with Bac, (ii) CNT functionalized Bac with arrow 
showing the baculovirus bound to CNT surface in magnifi ed image (iii). Scale bar indicates 100 nm length. Self-assembled nanocomplex of cationic 
PAA functionalized CNTs (f-CNT) were hybridized with anionic Bac. (iii) Cumulative release kinetics of baculovirus from denatured collagen hydrogel 
(2.5 mg mL −1 ) impregnated with Bac–CNT nanocomplex (v–viii–G) rMSCs were overlaid on the collagen hydrogel formulated with CNT (25 µg mL −1 ), 
BacMGFP, CNT/BacMGFP or functionalized CNT f-CNT/BacMGFP. Abbreviations: TEM = transmission electron microscope; CNT = carbon nanotube; 
rMSCs = rat mesenchymal stem cells; PAA = poly (acrylic acid), MGFP = Monster Green Fluorescent Protein. Reproduced with permission. [ 128 ] Copy-
right 2014, Elsevier. d) Thermo-responsive hydrogel for myocardial delivery of plasmid DNA. Thermosensitive sol-to-gel transition properties of bio-
degradable dextran-poly(e-caprolactone)-2-hydroxylethylmethacrylate-poly( N -isopropylacryl amide) (Dex-PCL-HEMA/PNIPAAm) hydrogel at 1.5 wt% 
concentration: (i) gel solution in fl uidity at room temperature, (ii) the gel solution turned into gel at 37 °C, and (iii) sol–gel reversibility of gel solution 
at room temperature. (iv) Representative pictures of left ventricles from each group after Masson’s Trichrome staining 30 d after treatments. Scale 
bar = 1 mm. Below images are the infarct size as percentages at 30 d. Infarct size is calculated as the ratio of infarcted to noninfarcted area of the left 
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addition of the fGO increased mechanical strength, reinforced 
the physical network of the composite hydrogels, and estab-
lished strong binding of fGO to plasmid DNA for eventual 
transfection to the host tissue. Biocompatibility of the formu-
lated hydrogel, evaluated using quantitative PCR and ELISA 
analysis of proinfl ammatory tumor necrosis factor α, was con-
fi rmed as the GO-GelMA nanocomplex did not induce any cyto-
toxic and infl ammatory effects. 
 Another study used hydrogels to overcome the drawbacks 
associated with the use of short interfering RNA (siRNA) to 
control gene expression, Figure  6 b. [ 127 ] The mechanism behind 
siRNA-based therapy is that the mRNA that is complementary 
to the siRNA is degraded and therefore after transcription, the 
gene expression process is inhibited as needed. This study 
used calcium cross-linked alginate, photo-cross-linked algi-
nate, and collagen biodegradable hydrogels to encapsulate both 
the cells and the siRNA responsible for knocking down their 
gene of interest, GFP. The siRNA present in the hydrogel had 
the ability to affect the incorporated cells as well as locally 
affect the surrounding cells in the host tissue. The degradation 
rates of the polymers chosen in this study greatly affected the 
results in silencing the gene of interest. Due to the fact that 
the alginate degrades quickly, this study confi rms that by using 
the degradation rates of different polymers, a sustained local 
release of siRNA can be delivered. When using these tech-
niques, the parameters of the specifi c application need to be 
taken into consideration to determine the most benefi cial time-
line of delivery. 
 Viral gene delivery systems have also been shown to be effec-
tive for myocardial regeneration therapy, Figure  6 c. In this case, 
hydrogels were used to deliver CNT hybridized baculoviruses 
to rat bone marrow stem cells. [ 128 ] These hydrogels were made 
up of a denatured collagen matrix containing MGFP gene car-
rying baculoviruses wrapped in single-walled carbon nano-
tubes. The hydrogel was shown to have greater mechanical 
properties and a more sustained delivery of the recombinant 
baculovirus to the cells. The group containing the functional-
ized gel showed a much greater number of MGPF expressing 
cells compared to the control group, the baculovirus group 
and the nonfunctionalized hydrogel group using fl uorescent 
microscopy. 
 Last, in a recent study, short-hairpin RNA (shRNA) of angi-
otensin converting enzyme was injected into rat myocardium 
postmyocardial infarction using a dextran-poly(e-caprolactone)-
2-hydroxylethylmethacrylate-poly( N -isopropylacrylamide) (Dex-
PCL-HEMA/PNIPAAm) hydrogel, Figure  6 d. [ 129 ] This study 
used the RNA interference gene-technique in order to silence 
the gene responsible for upregulation of angiotensin con-
verting enzyme (ACE). This is important in cardiac repair and 
remodeling because upregulation of ACE leads to cell apop-
tosis and increasing infarct size, both of which ultimately lead 
to heart failure. This study proved that the hydrogel sustained 
an extended gene expression of the shRNA responsible for the 
silencing gene-technique in vivo. Thirty days after intramyocar-
dial injection of the ACE-shRNA plasmid-loaded hydrogel they 
observed decreased ACE expression, inhibited cell apoptosis, 
reduced infarct size, and improved cardiac function. These 
results were better than either the hydrogel or the ACE-shRNA 
by itself. 
 6.  Conclusions and Future Perspectives 
 Injectable hydrogels offer huge potential for application in 
repair and regeneration of infarcted heart after MI. They can 
be used as carriers to deliver therapeutic drugs, biomolecules 
or cells to invoke a specifi c response in the infarcted heart tis-
sues, or to form functional cardiac tissue constructs for replace-
ment of infarcted cardiac tissues. In recent years, numerous 
hydrogels have been investigated for their application in car-
diac repair and regeneration. Several of these hydrogels have 
shown great promises toward achieving cardiac tissue repair. To 
date, no hydrogel composition has shown both the necessary 
biological and mechanical properties for suffi cient transition to 
clinical cardiac tissue repair. While naturally derived hydrogels 
from collagen, hyaluronic acid, chitosan, and ECM hydrogels 
have shown promise in the left ventricle modeling of the myo-
cardium, synthetic hydrogels have been shown to offer better 
control over their properties such as degradation time, gela-
tion time, and most importantly the mechanical stiffness of the 
hydrogel. 
 One school of thought is that hydrogels can induce stem 
cell homing. However, not much is known about the exchange 
of signals that take part in the movement of stem cells to an 
injured myocardium posthydrogel treatment. The importance 
of hydrogels also manifests itself in their ability to deliver 
drugs and chemical signals throughout the body to the heart. 
In such cases, targeted delivery and long-term controlled sus-
tained release are the advantages. Cytokines, such as the stem-
cell factor (SCF), granulocyte SCF, or stromal-cell-derived factor 
(SDF), may enhance cell transplantation and infi ltration. [ 130 ] 
When SCF was combined with G-SCF, a 250-fold increase in 
the number of circulating cells was made apparent in a model 
version. Cell microenvironments regulate and repair cellular 
fate and function. The ECM is a crucial element of the cell 
microenvironment that includes different chemical and phys-
ical cues. [ 131 ] Encapsulating cells in a suitable hydrogel before 
transplanting or injection also increases the chances for their 
survival, as it increases the cell-ECM interactions. This is why 
much attention has now been focused on hydrogels obtained 
from ECM molecules. These biomaterials are now made to rep-
licate ECM interactions, thus providing the best way to ensure 
the sustainability, survival and full function of the transplanted 
cells. [ 132 ] 
 Besides, the hydrogels can be specifi cally designed to help in 
myogenic differentiation. [ 133 ] Despite a considerable amount of 
research having been done on repair of infarcted heart tissue 
using injectable hydrogels in small animals such as rats, mice, 
and rabbits, research on application of hydrogel therapies on 
large primates and humans is still lacking. Thus, more inves-
tigations are required before the injectable hydrogel therapies 
with cells or biomolecules for cardiac repair are implemented in 
humans. Challenges in this endeavor include ensuring the sur-
vival and integration of the delivered cells in the cardiac envi-
ronment and their differentiation into the required myogenic 
phenotypes so that they can start performing like beating car-
diac cells in minimal time from the time of injection. Another 
challenge is the use of chemical cross-linking which can often 
be harmful for the cells. Photocrosslinking, ionic cross-linking, 
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options; however, application of these methods in situ is often 
diffi cult. Defi ciency of needed cells, the lack of full integration 
with the host tissue, and the absence of electrical communica-
tion through gap junctions are also among challenges that can 
compromise the success of the injectable hydrogel-based stem 
cell therapy or cardiac repair and require further research. 
Research has shown improvements in wall thickness, LV repair, 
and vascularization of the ischemic region with the use of 
injectable hydrogel based therapies. Studies performed so far 
in rodents and pigs give hope to the potential of hydrogel based 
therapies for cardiac repair in primates and humans. 
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